A therapeutic window for preventive therapy in NF1-associated optic pathway glioma

IF 2.6 Q3 ONCOLOGY

Molecular and Cellular Oncology Pub Date : 2021-11-02 DOI:10.1080/23723556.2021.1989262

Yuan Zhu, Wang Zheng, Emmanuelle S. Jecrois, Brianna R. Pierce, Daniel M. Treisman

引用次数: 1

Abstract

ABSTRACT Pediatric low-grade gliomas (pLGGs) are almost universally driven by abnormal activation of RAS-mediated MEK-ERK/MAPK signaling pathway. pLGGs predominantly occur in children, suggesting that they originate in an ERK-dependent neural stem/progenitor population(s) transiently present in the developing brain. Our recent preclinical study reveals a cell-lineage-of-origin and develops a chemopreventative therapeutic strategy.

查看原文本刊更多论文

nf1相关视神经胶质瘤预防性治疗的治疗窗口期

儿童低级别胶质瘤(pLGGs)几乎普遍由ras介导的MEK-ERK/MAPK信号通路异常激活驱动。pLGGs主要发生在儿童中，这表明它们起源于短暂存在于发育中的大脑中的erk依赖性神经干/祖细胞群。我们最近的临床前研究揭示了细胞谱系的起源，并开发了一种化学预防治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular and Cellular Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

3.20

自引率

0.00%

发文量

期刊介绍： For a long time, solid neoplasms have been viewed as relatively homogeneous entities composed for the most part of malignant cells. It is now clear that tumors are highly heterogeneous structures that evolve in the context of intimate interactions between cancer cells and endothelial, stromal as well as immune cells. During the past few years, experimental and clinical oncologists have witnessed several conceptual transitions of this type. Molecular and Cellular Oncology (MCO) emerges within this conceptual framework as a high-profile forum for the publication of fundamental, translational and clinical research on cancer. The scope of MCO is broad. Submissions dealing with all aspects of oncogenesis, tumor progression and response to therapy will be welcome, irrespective of whether they focus on solid or hematological neoplasms. MCO has gathered leading scientists with expertise in multiple areas of cancer research and other fields of investigation to constitute a large, interdisciplinary, Editorial Board that will ensure the quality of articles accepted for publication. MCO will publish Original Research Articles, Brief Reports, Reviews, Short Reviews, Commentaries, Author Views (auto-commentaries) and Meeting Reports dealing with all aspects of cancer research.